NCT02961374View on ClinicalTrials.gov

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 27, 2017

Primary Completion Date

February 23, 2020

Study Completion Date

September 27, 2021

Conditions
Attenuated Familial Adenomatous PolyposisFamilial Adenomatous Polyposis
Interventions
DRUG

Erlotinib

Given PO

DRUG

Erlotinib Hydrochloride

Given PO

Trial Locations (8)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

44195

Cleveland Clinic Foundation, Cleveland

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

55905

Mayo Clinic in Rochester, Rochester

77030

M D Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

85259

Mayo Clinic in Arizona, Scottsdale

00936

University of Puerto Rico, San Juan

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02961374 - Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer | Biotech Hunter | Biotech Hunter